How Will I Feel on Wegovy — and What Changes Are Normal?

The first injection: what those early days actually feel like

Picture this: it is the morning after your first 0.25mg Wegovy dose. You sit down for breakfast, and about halfway through you realise you are already full. That is not a placebo effect — it is semaglutide slowing gastric emptying and signalling fullness through GLP-1 receptors in the brain. The appetite change can feel almost startling at first, because the hunger that has probably been a constant backdrop simply quietens.

Alongside that, you may notice nausea. Not dramatic, for most people, more like the low-grade queasiness of a car journey. It tends to be worst in the first few days after a dose, then fades. Eating smaller portions, avoiding fatty or very rich foods, and staying well hydrated all help. Our prescribers share more specific coping strategies on the how to feel better on Wegovy page if you want practical detail.

Fatigue and mild headaches are also common in the first couple of weeks. Think of them as your body recalibrating to eating less, not a sign that something has gone wrong. Constipation or looser stools can appear too, sometimes in the same person at different times. If you want to understand the full range of physical and emotional changes people report, our guide on how Wegovy makes you feel covers everything from appetite shifts to mood in one place.

The honest acknowledgement: if you are reading this before your first dose, you are probably equal parts hopeful and nervous. That is entirely reasonable, and our overview of how people feel on Wegovy can help you understand what is typical before that first injection arrives. Most people find the first few weeks manageable; some find them rough. Knowing what is normal versus what needs a call to your prescriber makes a real difference.

Weeks four to twelve: dose increases and what they bring

The Wegovy titration schedule steps up roughly every four weeks, 0.25mg to 0.5mg, then 1.0mg, 1.7mg, and eventually 2.4mg maintenance. Each increase can bring a short revival of nausea or digestive discomfort, usually milder than the first time. Your system has already done this once; it tends to adapt faster.

By the time you reach a higher dose, most people report that the appetite suppression is more pronounced. Meals that once felt small now feel sufficient. The urge to snack, particularly on high-calorie foods, diminishes. Some people describe a shift in food preferences, previously irresistible foods feel less compelling. This is not willpower; it reflects how semaglutide interacts with reward pathways in the brain, as documented in the NHS patient information for semaglutide.

Weight loss typically becomes measurable in this period. The STEP 1 trial, published in the New England Journal of Medicine, recorded around 15% average body-weight reduction over 68 weeks at 2.4mg, changes that accumulate gradually rather than arriving all at once. For a fuller breakdown of when effects tend to become noticeable, the timeline of semaglutide's effects sets out what the evidence shows.

Energy levels for many people improve once nausea settles and weight begins to shift. Some report sleeping better; others notice that physical activity feels less effortful. Neither is guaranteed, and results vary between individuals.

Side effects worth knowing, and one you should not ignore

The common side-effect profile is gastrointestinal: nausea, vomiting, diarrhoea, constipation, reflux, burping. These are listed in full in the patient information leaflet supplied with every Wegovy pen, and the Wegovy treatment page summarises what the clinical data shows.

Most of these are mild to moderate and temporary. Serious side effects are rare but real. In January 2026, the MHRA issued a Drug Safety Update specifically highlighting acute pancreatitis as an infrequent risk with GLP-1 medicines. The symptom to act on immediately is severe stomach pain, pain that persists, does not shift with position, and may radiate towards the back, sometimes with vomiting. That combination warrants urgent medical assessment, not a wait-and-see approach.

Gallbladder problems, injection-site reactions, and dizziness are also documented. If you notice anything unexpected or worrying, report it via the Yellow Card scheme at the MHRA and contact your prescriber. Suspected side effects can also be flagged at yellowcard.mhra.gov.uk.

Wegovy is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. It is not licensed for under-18s. If any of those circumstances apply or change during treatment, speak to your prescriber promptly.

Beyond side effects: the broader experience of being on Wegovy

People on longer-term Wegovy often describe a quieter relationship with food. The constant mental negotiation (what to eat, whether to have more, guilt after meals) eases for many. That psychological shift can feel as significant as the number on the scales.

Physical changes compound over months. Clothes fit differently. Blood pressure and cholesterol markers sometimes improve alongside weight. Whether those benefits apply to you specifically is something your prescriber tracks through regular reviews. At nume, a prescriber re-assesses your case before every repeat order, not as a formality, but to catch any emerging concerns and to confirm the treatment is doing what it should. You can see how that process works on the treatment consultation page.

Cost is a real consideration on a longer treatment course. The Wegovy availability and pricing guide explains what a legitimate private prescription typically includes and what to check before committing to any provider. Price alone is the wrong guide for a prescription medicine; what matters is that the supply chain is genuine, the clinical oversight is real, and you have somewhere to turn if something changes.

If you are weighing this up and want a prescriber to look at your individual situation, speak to our prescribers through a free consultation, reviewed the same day your information is submitted, by a GPhC-registered Independent Prescriber.